Trial Profile
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms CAPTIVATE
- Sponsors Pharmacyclics
- 12 Dec 2023 Results reporting retreatment outcomes and updated data with an additional year of follow-up (up to 5 years) from FD cohort presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Dec 2023 According to a Janssen media release, new long-term follow-up data from this trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
- 11 Dec 2023 Results presented in the Janssen Media Release.